Genital Diseases, Female  >>  gedatolisib (PF-05212384)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
gedatolisib (PF-05212384) / Celcuity
NCT01420081 / 2011-003062-32: A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

Terminated
2
67
Canada, Japan, US, Europe, RoW
PF-05212384, PKI-587
Pfizer
Endometrial Neoplasms
04/14
12/15

Download Options